A Potential Prognosis and Immune Biomarker in Cancer: DICER1

Background: DICER1 plays a significantly important role in short dsRNA-mediated post-transcriptional gene silencing that is deeply embedded in the network of cancer genes. Aberrant expression and mutation of DICER1 have been studied and reported to be closely associated with tumorigenesis and development, while lower levels of DICER1 mRNA or protein are associated with poorer prognosis in some cancers. However, there is little research about the effect and mechanism of mutated DICER1. Materials: and Methods: In our study, DICER1 mutation in the TCGA database from the top 10 cancers were analyzed to explore the effect of DICER1 mutants in cancer prognosis and the possible potential mechanisms. Results: : We found that DICER1 mutation was closely related to better clinical outcomes in pan-cancer and uterine corpus endometrial carcinoma (UCEC) treatment, which meant that DICER1 could be served as a prognosis factor for pan-cancer, especially UCEC. And mechanism research indicated that DICER1-mut facilitated antitumor immunity, which could be the potential mechanism for DICER1-mut prognosis value. Moreover, tumor microenvironment (TME) features and higher TMB of DICER1-mut manifested that DICER1 may be a potential biomarker of immunotherapy, which needed more clinical and basic research to validate. Conclusions: : In summary, our finding suggested that DICER1 may be a potential prognostic biomarker and was associated with TME in UCEC. In addition, it might be a marker of immunotherapy.